Back to search

University of Ioannina

Σύγκριση πλειοτροπικών δράσεων υπολιπιδαιμικών θεραπειών

Abstract

dc:description

Introduction: Statins may exhibit effects, which are independent of their lipidloweringeffects. Among them are anti-inflammatory, anti-oxidant effects, uric-acid loweringeffects as well as effects on glucose metabolism. Whether different statins at equivalentdoses (depending on their lipophilicity) or the combination of low-dose statin with ezetimibehave comparable pleiotropic effects is unknownAim: The aim οf this thesis was to compare the effects of different statins or thecombination of a statin with ezetimibe at equivalent low-density lipoprotein cholesterollowering doses on several inflammatory, oxidative stress, uric acid und glycemic parametersin subjects with hypercholesterolemia.Methods: Protocol 1. We enrolled one hundred and fifty three (n = 153)hypercholesterolemic subjects who were randomized to receive simvastatin 40 mg orsimvastatin/ezetimibe 10/10 mg or rosuvastatin 10 mg daily.We measured (at baseline and following 12 weeks of treatment):- Oxidative Stress parameters:1) Plasma 8-Epi prostaglandin F2 alpha (8-epiPGF2a)2) Oxidized LDL (oxLDL)- Inflammatory parameters:1) Lipoprotein associated phospholipase A2 (Lp-PLA2) activity and mass- Glucose metabolism parameters1) Homeostasis model assessment of insulin resistance (HOMA-IR),2) Fasting insulin levels,3) Fasting plasma glucose (FPG),4) Glycosylated hemoglobin (HbA1c),5) HOMA of β-cell function (HOMA-B)- Uric acid metabolism parameters1) Serum uric acid levels,2) Fractional excretion of uric acid,3) Renal function parametersProtocol 2: We enrolled sixty (n = 60) hypercholesterolemic subjects who wererandomized to receive either simvastatin 40 mg or simvastatin/ezetimibe 10/10 mg daily.We measured (at baseline and following 12 weeks of treatment):-ΤLR2 and TLR4 membrane expression in monocytes, LPS-induced intracellularproduction of IL-1β and IL-6 in both patient groups, as well as in 30 age- and sexmatchednormolipidemic controls.Results: Protocol 1: A significant reduction in plasma 8-isoprostane and oxLDL levelswas observed in all treatment groups [by 10%, 8% and 6% (p < 0.05 compared with baseline)and 41%, 40% and 39% (p < 0.001 compared with baseline) in simvastatin,simvastatin/ezetimibe and rosuvastatin groups, respectively]. In all treatment groups asignificant reduction in total plasma Lp-PLA2 activity and mass was observed (by 36%, 31%and 38% and 36%, 32% and 32% for simvastatin, simvastatin/ezetimibe and rosuvastatin,respectively, p < 0.001 compared with baseline). No intergroup differences were observed.All 3 treatment regimens were associated with significant increases in HOMA-IR andfasting insulin levels (p<0.05 compared with baseline). No significant difference wasobserved between groups. No change in FPG, HbA1c and HOMA-B levels compared withbaseline were noted in any of the 3 treatment groups.A significant reduction of serum uric acid levels was seen in all treatment groups(simvastatin/ezetimibe 10/10 mg: -3.8%, simvastatin 40 mg: -5.7% and rosuvastatin 10 mg: -3.8%; p<0.05 compared with baseline; p=NS for comparison between groups). Fractionalexcretion of uric acid non-significantly increased in all groups (simvastatin/ezetimibe 10/10mg: +6.8%, simvastatin 40 mg: +6.8% and rosuvastatin 10 mg: +5.9%). The reduction inserum uric acid levels correlated with the increase in fractional excretion of uric acid andbaseline uric acid levels. Renal function parameters as well as serum levels and fractionalexcretions of electrolytes remained unchanged in all groups.Protocol 2: Hypercholesterolemic patients exhibited higher TLR2 and TLR4 membraneexpression compared with controls (p < 0.02). LPS induced a significant increase in theintracellular levels of IL-1β and IL-6 in all groups however both patient groups exhibitedsignificantly lower levels compared with controls. Three months of treatment with eithersimvastatin or its combination with ezetimibe resulted in a significant reduction of TLR2 andTLR4 expression (p<0.01 compared with baseline values) with no intergroup differences.Furthermore, in both groups the post-treatment values of LPS-induced IL-1β and IL-6production were significantly lower compared with baseline (p<0.05 for all comparisons).Conclusions: Simvastatin 40 mg, simvastatin/ezetimibe 10/10 mg and rosuvastatin 10mg significantly reduced 8-epiPGF2a, oxLDL and Lp-PLA2 activity and mass to a similarextent.To the extent that simvastatin 40 mg, rosuvastatin 10 mgand simvastatin/ezetimibe 10/10 mg are associated with adverse effects oninsulin resistance, they appear to be of the same magnitude.Simvastatin/ezetimibe 10/10 mg, simvastatin 40 mg and rosuvastatin 10 mg exhibit asimilar uric acid lowering effect.Protocol 2: A high simvastatin dose or the combination of a low-dose simvastatin withezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS induced IL-6and IL-1β production in monocytes of hypercholesterolemic patients

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Moutzouri, Elisavet
  • Μουτζούρη, Ελισάβετ

Subjects

dc:subject × 20

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/39629

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Moutzouri, Elisavet; Μουτζούρη, Ελισάβετ. Σύγκριση πλειοτροπικών δράσεων υπολιπιδαιμικών θεραπειών. University of Ioannina, 2015. http://hdl.handle.net/10442/hedi/39629